Home › Funds › Deep Track Capital, LP › MLTX
Deep Track Capital, LP position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
Deep Track Capital, LP reported holding 6,999,025 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$136.3M, representing 2.03% of its reported portfolio and ranking #19 among its reported holdings. Deep Track Capital, LP has disclosed MLTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Deep Track Capital, LP's MLTX position evolved
Deep Track Capital, LP first disclosed a stake in MLTX in Q4 2025 at 4,610,071 shares (US$60.8M). The position peaked in Q2 2026 at 6,999,025 shares, worth US$136.3M. Across 3 filings, Deep Track Capital, LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 6,999,025 shares valued at US$136.3M — an increase of 590,162 shares quarter over quarter.. Notable position changes include a 39% increase in Q1 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 4.61M | $60.76M | New |
| Q1 2026 | 6.41M | $119.46M | Add |
| Q2 2026 | 7.00M | $136.27M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 29 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Cormorant Asset Management, LP (US$62.4M), Logos Global Management LP (US$52.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $311.54M · Q2 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- Logos Global Management LP 2.67M sh · $52.08M · Q2 2026
- Weiss Asset Management LP 2.58M sh · $50.27M · Q2 2026
- MPM BioImpact LLC 1.61M sh · $31.29M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $27.26M · Q2 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Trails Edge Capital Partners, LP 750.00K sh · $14.60M · Q2 2026
More on Deep Track Capital, LP
FAQ
How long has Deep Track Capital, LP held MLTX?
Deep Track Capital, LP has disclosed MLTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Deep Track Capital, LP's current position in MLTX?
As of Q2 2026, Deep Track Capital, LP holds 7.00M shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $136.27M, representing 2.03% of its reported portfolio and ranking #19.
Has Deep Track Capital, LP been buying or selling MLTX?
In the latest 13F filing (Q2 2026), Deep Track Capital, LP increased its position in MLTX. The position peaked in Q2 2026 at 7.00M shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Cormorant Asset Management, LP, Logos Global Management LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.